The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.

The G20210A mutation in the prothrombin gene is associated with an increased risk of a first venous thromboembolic episode; few data are available about the long‐term risk for recurrent venous thromboembolism and it is not known whether or not carriers of the mutation should be recommended lifelong anticoagulant treatment after the first thrombosis. We investigated 624 patients, referred for previous objectively documented deep venous thrombosis of the legs or pulmonary embolism, to determine the risk of recurrent thromboembolism in heterozygous carriers of the G20210A mutation in the prothrombin gene after the first episode of venous thromboembolism. After exclusion of other inherited (anti‐thrombin, protein C, protein S deficiency and factor V Leiden) or acquired (anti‐phospholipid antibody syndrome) causes of thrombophilia, 52 heterozygous carriers of the prothrombin mutation were compared with 283 patients with normal genotype. The relative risk for recurrent venous thromboembolism was calculated between groups using a Cox's proportional hazard model. The patients with the prothrombin mutation had a risk for spontaneous recurrent venous thromboembolism similar to that of patients with normal genotype (hazard ratio 1·3; 95% CI, 0·7–2·3). The circumstances of the first event (spontaneous or secondary) did not produce any substantial variation in the risk for recurrence. In conclusion, the carriers of the prothrombin mutation should be treated with oral anticoagulants after a first deep venous thrombosis for a similar length of time as patients with a normal genotype.

[1]  T. Baglin,et al.  Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′‐untranslated region of the prothrombin gene , 1997, British journal of haematology.

[2]  Vittorio Pengo,et al.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.

[3]  V. Nicaud,et al.  Venous Thromboembolic Disease and the Prothrombin, Methylene Tetrahydrofolate Reductase and Factor V Genes , 1999, Thrombosis and Haemostasis.

[4]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[5]  M. Margaglione,et al.  Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[6]  M. Prins,et al.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. , 2000, Blood.

[7]  R. Simon,et al.  Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.

[8]  A. Cumming,et al.  The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population , 1997, British journal of haematology.

[9]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[10]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[11]  E. Oger,et al.  Prevalence of 20210 A Allele of the Prothrombin Gene in Venous Thromboembolism Patients , 1998, Thrombosis and Haemostasis.

[12]  M. Makris,et al.  Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia , 1997, Thrombosis and Haemostasis.

[13]  J. Vandenbroucke,et al.  Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). , 1997, Blood.

[14]  P. Mannucci,et al.  Inherited thrombophilia: pathogenesis, clinical syndromes, and management. , 1996, Blood.

[15]  E. Taioli,et al.  The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. , 1999, Thrombosis research.

[16]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[17]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[18]  M. Margaglione,et al.  Increased Risk for Venous Thrombosis in Carriers of the Prothrombin GA20210 Gene Variant , 1998, Annals of Internal Medicine.

[19]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[20]  G. Leone,et al.  Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. , 1998, Blood.

[21]  E. Minar,et al.  The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[22]  P. Chiusolo,et al.  Prevalence of the Factor II G20210A Mutation in Symptomatic Patients with Inherited Thrombophilia , 1998, Thrombosis and Haemostasis.

[23]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.